<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527537</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00030802</org_study_id>
    <nct_id>NCT03527537</nct_id>
  </id_info>
  <brief_title>Threshold for Initiation of Medical Treatment for Women With Gestational Diabetes</brief_title>
  <acronym>TIME</acronym>
  <official_title>Threshold for Initiation of Medical Treatment for Women With Gestational Diabetes: A Single Site Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to compare two different thresholds for initiation of medical
      treatment for GDM. Pregnant women diagnosed with GDM will be randomized to either start
      pharmacotherapy when they have reached at least 20% or at least 40% of capillary blood
      glucose (CBG) values above the target goal. The investigators hypothesize that a lower
      threshold of 20% elevated CBG levels, compared to 40%, will lead to lower rates of obstetric
      and medical complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gestational diabetes mellitus (GDM) affects 5-8% of pregnant women, many of whom will require
      treatment beyond diet and exercise. Despite this high prevalence, there is no consensus
      regarding the glycemic threshold for conversion from diet to medical treatment for GDM. No
      randomized studies have been performed on how to define failure with diet and exercise and
      currently, the need to start insulin or oral hypoglycemic agents is at the provider's
      discretion. It is important to establish criterion of pharmacotherapy initiation for GDM in
      pregnancy as GDM under-treatment leads to increased rates of adverse obstetric outcomes
      associated with poor glycemic control including macrosomia, pre-eclampsia, cesarean delivery,
      shoulder dystocia, birth trauma, neonatal hypoglycemia and hyperbilirubinemia, childhood
      obesity and metabolic syndrome in the offspring. In contrast, overtreatment for women comes
      at increased cost due to overutilization of resources, increased expense, and adverse effects
      of the medications themselves.

      The goal of this study is to compare two different thresholds for initiation of medical
      treatment for GDM. Pregnant women diagnosed with GDM (N=284) will be randomized to either
      start pharmacotherapy when they have reached at least 20% or at least 40% of capillary blood
      glucose (CBG) values above the target goal. The investigators hypothesize that a lower
      threshold of 20% elevated CBG levels, compared to 40%, will lead to lower rates of obstetric
      and medical complications.

      Aim 1: To compare the rate of a composite outcome between two thresholds for medical
      treatment initiation for GDM. Women who receive the diagnosis of GDM and meet eligibility
      criteria will be randomized to start insulin or an oral hypoglycemic agent when the number of
      CBG values above target reaches 20% or 40%. The primary outcome will be a composite of
      neonatal macrosomia, shoulder dystocia, neonatal hypoglycemia, neonatal hyperbilirubinemia,
      preterm delivery, neonatal intensive care unit (NICU) admission, and stillbirth or neonatal
      death. The investigators hypothesize that women who receive treatment with stricter limits of
      abnormal blood glucose levels will have lower rates of these poor outcomes.

      Aim 2: To compare the rates of cesarean delivery between two thresholds for medical treatment
      initiation for GDM. The investigators hypothesize that women who receive treatment with
      stricter limits of abnormal blood glucose levels will have lower rates of cesarean delivery.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a randomized, controlled trial of 284 women with a diagnosis of GDM. Women will be consented and randomized at the time of their diagnosis. All women with GDM will receive counseling regarding diet and exercise and instructions on self-monitoring blood glucose values. The investigators will apply cutoffs of 95 mg/dL for fasting and 120 mg/dL for 2-hour post-prandial levels. Once randomized, the first treatment arm will be assigned to a limit of 20% abnormal values before we start treatment and to titrate up dosages as needed, while using the 20% threshold of abnormal CBG values at each subsequent review of glucose log. To specify, if more than 20% of values for the week are elevated, treatment would be initiated. Once treatment is initiated, the dosage of medication will be adjusted with cutoff of 20% of abnormal values per week. The second treatment arm will utilize the same protocol, however, the limit to start medications or adjust dosages will be 40% abnormal values.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Neonatal Outcome</measure>
    <time_frame>The data will be collected up to 6 months of life</time_frame>
    <description>Our primary outcome will be a composite of neonatal macrosomia, shoulder dystocia, neonatal hypoglycemia, neonatal hyperbilirubinemia, preterm delivery, neonatal intensive care unit (NICU) admission, and stillbirth or neonatal death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cesarean Delivery Rate</measure>
    <time_frame>The data will be collected up to 6 weeks postpartum</time_frame>
    <description>Our secondary outcome will be to compare the rates of cesarean delivery between two thresholds for medical treatment initiation for GDM.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>20% cutoff group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment intervention will be initiated with glyburide, metformin, or insulin if 20% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40% cutoff group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment intervention will be initiated with glyburide, metformin, or insulin if 40% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin may be administered base on glucose log values. The dosing of the insulin will be decided by the provider using typical management of gestational diabetes.</description>
    <arm_group_label>20% cutoff group</arm_group_label>
    <arm_group_label>40% cutoff group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyburide</intervention_name>
    <description>Glyburide may be administered base on glucose log values. The dosing of the glyburide will be decided by the provider using typical management of gestational diabetes.</description>
    <arm_group_label>20% cutoff group</arm_group_label>
    <arm_group_label>40% cutoff group</arm_group_label>
    <other_name>Glynase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin may be administered base on glucose log values. The dosing of the metformin will be decided by the provider using typical management of gestational diabetes.</description>
    <arm_group_label>20% cutoff group</arm_group_label>
    <arm_group_label>40% cutoff group</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Viable singleton pregnancy

          -  Age &gt;= 18 years old

          -  Diagnosed with gestational diabetes mellitus

        Exclusion Criteria:

          -  Pre-gestational diabetes

          -  Significantly abnormal blood glucose testing, suggestive of the presence of
             pre-gestational diabetes

          -  Women who check blood sugars on average less than 2 times per day after appropriate
             counseling
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only women will be randomized as this is a pregnancy-focused study</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Palatnik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meredith Cruz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel K Harrison, MD</last_name>
    <phone>414-805-6023</phone>
    <email>rharrison@mcw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Palatnik, MD</last_name>
    <phone>414-805-6627</phone>
    <email>apalatnik@mcw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Committee on Practice Bulletinsâ€”Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol. 2018 Feb;131(2):e49-e64. doi: 10.1097/AOG.0000000000002501.</citation>
    <PMID>29370047</PMID>
  </reference>
  <reference>
    <citation>Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. Ann Intern Med. 2013 Jul 16;159(2):123-9. doi: 10.7326/0003-4819-159-2-201307160-00661. Review.</citation>
    <PMID>23712381</PMID>
  </reference>
  <reference>
    <citation>Langer O, Yogev Y, Most O, Xenakis EM. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol. 2005 Apr;192(4):989-97.</citation>
    <PMID>15846171</PMID>
  </reference>
  <reference>
    <citation>Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005 Jun 16;352(24):2477-86. Epub 2005 Jun 12.</citation>
    <PMID>15951574</PMID>
  </reference>
  <reference>
    <citation>Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, Wapner RJ, Varner MW, Rouse DJ, Thorp JM Jr, Sciscione A, Catalano P, Harper M, Saade G, Lain KY, Sorokin Y, Peaceman AM, Tolosa JE, Anderson GB; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009 Oct 1;361(14):1339-48. doi: 10.1056/NEJMoa0902430.</citation>
    <PMID>19797280</PMID>
  </reference>
  <reference>
    <citation>Athukorala C, Crowther CA, Willson K; Austrailian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Women with gestational diabetes mellitus in the ACHOIS trial: risk factors for shoulder dystocia. Aust N Z J Obstet Gynaecol. 2007 Feb;47(1):37-41.</citation>
    <PMID>17261098</PMID>
  </reference>
  <reference>
    <citation>Gilbert WM, Nesbitt TS, Danielsen B. Associated factors in 1611 cases of brachial plexus injury. Obstet Gynecol. 1999 Apr;93(4):536-40.</citation>
    <PMID>10214829</PMID>
  </reference>
  <reference>
    <citation>Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005 Mar;115(3):e290-6.</citation>
    <PMID>15741354</PMID>
  </reference>
  <reference>
    <citation>Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Lauenborg J, Schmidt L, Damm P. Overweight and the metabolic syndrome in adult offspring of women with diet-treated gestational diabetes mellitus or type 1 diabetes. J Clin Endocrinol Metab. 2009 Jul;94(7):2464-70. doi: 10.1210/jc.2009-0305. Epub 2009 May 5.</citation>
    <PMID>19417040</PMID>
  </reference>
  <reference>
    <citation>Dabelea D, Snell-Bergeon JK, Hartsfield CL, Bischoff KJ, Hamman RF, McDuffie RS; Kaiser Permanente of Colorado GDM Screening Program. Increasing prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: Kaiser Permanente of Colorado GDM Screening Program. Diabetes Care. 2005 Mar;28(3):579-84.</citation>
    <PMID>15735191</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012 Jan;35 Suppl 1:S64-71. doi: 10.2337/dc12-s064.</citation>
    <PMID>22187472</PMID>
  </reference>
  <reference>
    <citation>HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008 May 8;358(19):1991-2002. doi: 10.1056/NEJMoa0707943.</citation>
    <PMID>18463375</PMID>
  </reference>
  <reference>
    <citation>Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002 Oct;25(10):1862-8. Review.</citation>
    <PMID>12351492</PMID>
  </reference>
  <reference>
    <citation>Caissutti C, Berghella V. Scientific Evidence for Different Options for GDM Screening and Management: Controversies and Review of the Literature. Biomed Res Int. 2017;2017:2746471. doi: 10.1155/2017/2746471. Epub 2017 Apr 10. Review.</citation>
    <PMID>28497042</PMID>
  </reference>
  <reference>
    <citation>Rumbold AR, Crowther CA. Guideline use for gestational diabetes mellitus and current screening, diagnostic and management practices in Australian hospitals. Aust N Z J Obstet Gynaecol. 2001 Feb;41(1):86-90.</citation>
    <PMID>11284655</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. 13. Management of Diabetes in Pregnancy. Diabetes Care. 2017 Jan;40(Suppl 1):S114-S119. Review.</citation>
    <PMID>27979900</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2018</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Anna Palatnik, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

